Method1 | # IV | Exp. var.2 (%) | OR | 95% CI | p-val | Q p-val3 | intercept p-val4 | ||
---|---|---|---|---|---|---|---|---|---|
Main analysis | |||||||||
Two-sample MR | IVW | 134 | 38.5 | 0.988 | 0.987 | 0.990 | 1.4 × 10–44 | > 0.99 | |
Sensitivity analyses | |||||||||
Two-sample MR | Egger | 134 | 38.5 | 0.990 | 0.983 | 0.996 | 2.6 × 10–03 | > 0.99 | 0.66 |
Two-sample MR | WM | 134 | 38.5 | 0.988 | 0.986 | 0.991 | 5.0 × 10–22 | ||
expl. Variance ~ 8%5 | IVW | 17 | 8.4 | 0.990 | 0.986 | 0.993 | 6.7 × 10–09 | 0.94 | |
HGDP as reference6 | IVW | 133 | 37.9 | 0.988 | 0.987 | 0.990 | 7.4 × 10–44 | > 0.99 | |
refined Mexican reference7 | IVW | 134 | 38.6 | 0.988 | 0.987 | 0.990 | 7.7 × 10–44 | > 0.99 | |
Stratified analyses | |||||||||
BC diagnosed ≤ 45 y8 | IVW | 136 | 39.3 | 0.994 | 0.991 | 0.997 | 1.4 × 10–04 | > 0.99 | |
Familial BC9 | IVW | 132 | 37.4 | 0.973 | 0.969 | 0.978 | 1.0 × 10–33 | > 0.99 | |
ER-positive BC10 | IVW | 135 | 38.5 | 0.989 | 0.986 | 0.991 | 6.6 × 10–18 | > 0.99 | |
ER-negative BC | IVW | 139 | 40.2 | 1.004 | 1.001 | 1.008 | 1.5 × 10–02 | > 0.99 | |
Triple-negative BC11 | IVW | 142 | 40.3 | 1.004 | 0.999 | 1.009 | 0.11 | > 0.99 |